December 2014 Volume 10, Issue 12
Volume 10, Issue 12 | December 2014
December 2014
In this Issue
Diagnostics
LabCorp sets $6.1B price tag on Covance
Companies say combined unit will be world’s leading healthcare diagnostics companyWaiting to exhale
MIT finds new diagnostic tool in capnograph analysis of CO2 in patients’ breathUrine test may prove to be golden
Data published in Cancer Discovery show ability to test tumor status from urineA mind to predict diabetes
Set of molecules found to link insulin resistance in the brain to diabetesMyriad, AbbVie expand CDx agreement
Deal comes on heels of positive study data on Myriad’s Tumor BRACAnalysis CDxResearch & Development
Compugen validates cancer immunotherapy prospect
Company’s immune checkpoint candidate shows potential for development of multiple cancer immunotherapiesMaking a difference with microtissue
Seahorse Bioscience and Moffitt seek a method of metabolism measurement for cancer treatmentFrom stem cells to insulin-producing cells
Harvard takes giant step toward new diabetes treatment, producing billions of beta cells from stem cellsProtein partnership
Proteostasis Therapeutics and Astellas partner to modulate the unfolded protein responseChanging the cycle
Partnership between Idera and PPMD aims for Duchenne cureNIH funds study of more than 200 rare diseases
Physician scientists at 22 consortia will collaborate with representatives of 98 patient advocacy groups to advance clinical research and investigate new treatments for patients with rare diseasesClinical Trials
Patient perspective
Conference seeks inclusion of patient-focused endpoints in future brain cancer trialsIn like FLINT
Intercept drug tackles liver disease known as nonalcoholic steatohepatitisGoing after celiac disease
BioLineRx declares Phase 1/2 study for new celiac treatment a success, but it won’t replace a gluten-free dietA ClinIntel-ligent transaction
PAREXEL boosts clinical RTSM offerings with ClinIntel buyCelldex presents varlilumab proof-of-concept data
Favorable safety profile, clear immunological effects and clinical activity position therapeutic for future studiesFeature
PepTalk welcomes you back to sunny San Diego
Conference offers an array of education, innovation and networking programs to help attendees gain new perspectives on the evolution of biologicsQ&A
Q&A: The year that was; the year that will be
DDNews speaks with two CEOs (Ron Squarer of Array BioPharma Inc. and Dr. Brad Thompson of Oncolytics Biotech) with an eye toward the recent past and near future of cancer therapeutics and life-sciences business trendsCommentary
Publishers' commentary: A decade down and more to come
DDNews’ publishers give you an update on why the magazine continues to thrive and how it serves the needs of you, the reader, as well as letting you know about some of the changes it has undergone over the past year, both in the physical issue and onlineWorking at science, science at work
How can students best prepare for an actual career in life sciences? DDNews columnist Peter Kissinger attempts to sort out that tricky question.Guest commentary: Clinical trial data inaccuracies--Challenges for personalized medicine
Recent scrutiny puts trial results in question. How big is the problem, and what can be done to put things back on course?Business & Government Policy
Aegerion acquires orphan drug Myalept for $325M
Commercialization of generalized lipodystrophy drug expected to bring synergy, near-term revenueCertara awarded $400,000 by FDA
Three-year grant supports expansion of PBPK modeling platformPDL BioPharma acquires bulk of Cerdelga royalty interest
The company pays the University of Michigan $65.6 million for Gaucher disease treatment royaltiesOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsDiscovery
Understanding East vs. West
Largest genomic study of liver cancer identifies mutations that distinguish Asian and Western diseasePersonalized cancer therapeutics
Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescenceOn the hunt against Huntington’s disease
Charles River rides trending CRO growth, extends CHDI Huntington’s disease collaborationHigh-throughput detection for discovery
Molecular Devices partners with Roche to develop custom ruthenium Nano-TRF detection platformPreclinical
RNA delivery coming of age?
Data supportive of GEN-2 presented at the miRNA World Conference Workshop on miRNA deliveryStopping the bleeding
Synthetic peptide-based device promotes hemostasis and healingA French connection in oncology
Innate Pharma describes cutaneous T cell lymphoma therapeutic in scientific journal Cancer ResearchGVK BIO to acquire Vanta Bioscience
Deal provides GVK BIO with GLP toxicology services in several areas, including pharmaceuticalsProvantis helps increase efficiencies
Chinese research institute chooses Provantis’ preclinical software solution for Shanghai headquarters
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Harnessing liver-on-a-chip models for drug safety
Discover how researchers leverage microphysiological systems in toxicology studies.
Enhancing bioanalytical studies with centralized data management
Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Explained: How are metabolite biomarkers improving drug discovery and development?
By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
